Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Log inSign up
Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Blog
Job Board
Q3AS

© 2026 Aqora Quantum S.A.S.

TermsPrivacyLegal Notice

European Journal of Cancer

Unlocking clinical quantum oncology through quantum control

Bruno F. E. Matarèse, Arnie D. Purushotham

Published Jul 15, 2025• 7 citations
Publisher
DOI
10.1016/j.ejca.2025.115632

Related papers

Quantum oncology

E.L. Albuquerque

Annual reports in medicinal chemistry•Jan 1, 2026•0 citations

Quantum computing for oncology

Siddhi Ramesh, Teague Tomesh, Samantha J. Riesenfeld +2 more

Nature Cancer•May 17, 2024•12 citations

Quantum Oncology: The Applications of Quantum Computing in Cancer Research

Jiaran Li, Li Li, Ning Liu +3 more

Journal of Medical Systems•Jul 23, 2025•6 citations

Quantum Oncology

Bruno F. E. Matarèse, Arnie D. Purushotham

Quantum core technologies (computing, sensing, imaging, communication) hold immense promise for revolutionizing cancer care. This paper explores their distinct capabilities in early-stage cancer diagnosis, improved clinical workflows, drug discovery, and personalized treatment. By overcoming challenges such as infrastructure and ethical considerations, these processes can unlock faster diagnoses, optimize therapies, and enhance patient outcomes.

Quantum Reports•Feb 18, 2025•17 citations

The Rise of Generalist Foundation Models and Quantum Computing in Oncology

Manish Kakar

In the field of oncology, Artificial intelligence (AI) and deep learning (DL) are an essential component of decision-support. However, traditional narrow-AI models have significant limitations in clinics with respect to narrow, task-specificity (TS), high data requirement and interpretability. Moreover, the absence of common clinical criteria and the lack of doctors in the co-development of explainable AI (XAI) have undermined the implementation causing conflict with general data protection regulation (GDPR), trust and ethical integration requirements. The application of AI/DL tools in clinics are often constrained by TS, heavy dependency on hyperparameter tuning and large data volume. This review fills in these gaps by creating a cohesive framework that links problem-driven clinical demands with emerging technologies, specifically, the convergence of Generalist Medical AI (GMAI) and Quantum Oncology (QO). Although GMAI's use foundation models, have high computational requirements and have inherent complexity in their validation pipelines, they are designed to be based on self-supervised learning from multimodal data to address a range of downstream clinical tasks. This review aims to critically discuss the potential of quantum computing (QC) to augment GMAI for more efficient data processing, medical imaging, drug discovery, and genomic analysis, owing to the inherent strengths of quantum superposition and entanglement that surpass the capabilities of classical AI/DL systems. Structural and technical trade-offs of this paradigm change are also discussed. We also give recommendations for safe bedside translation by facilitating a common assessment through clinician in the loop design, the CLAIM checklist, and the framework FUTURE-AI. Finally, this analysis outlines oncology and quantum convergence into quantum oncology (QO). This enables scalable, sustainable, and precision oncology while respecting ethics and privacy.

Technology in Cancer Research & Treatment•Aug 1, 2026•0 citations

Quantum Machine Learning in Oncology: A Systematic Review of Clinical Applications, Challenges, and Future Research Directions

Yanche Ari Kustiawan, Khairil Imran Ghauth

This research project presents a PRISMA-guided systematic literature review exploring the application of quantum machine learning (QML) in oncology, a rapidly growing field with fragmented evidence. The study synthesizes peer-reviewed studies from six databases (ACM, IEEE, MDPI, Scopus, Wiley, and PubMed) published between 2020 and 2026, screening 212 records and selecting 49 studies for analysis. The review examines clinical tasks, cancer domains, QML architectures, challenges, and future directions, revealing that current research mainly focuses on classification and detection, particularly in breast cancer and brain tumors, using hybrid quantum-classical models. Despite promising results, progress is limited by hardware constraints, simulator dependence, and insufficient clinical validation. The findings provide a clear overview of current QML trends and highlight future priorities, including real quantum hardware testing, diverse clinical datasets, standardized benchmarking, and stronger collaboration between computing and oncology communities.

•Jul 12, 2026•0 citations
In the field of oncology, Artificial intelligence (AI) and deep learning (DL) are an essential component of decision-support. However, traditional narrow-AI models have significant limitations in clinics with respect to narrow, task-specificity (TS), high data requirement and interpretability. Moreover, the absence of common clinical criteria and the lack of doctors in the co-development of explainable AI (XAI) have undermined the implementation causing conflict with general data protection regulation (GDPR), trust and ethical integration requirements. The application of AI/DL tools in clinics are often constrained by TS, heavy dependency on hyperparameter tuning and large data volume. This review fills in these gaps by creating a cohesive framework that links problem-driven clinical demands with emerging technologies, specifically, the convergence of Generalist Medical AI (GMAI) and Quantum Oncology (QO). Although GMAI's use foundation models, have high computational requirements and have inherent complexity in their validation pipelines, they are designed to be based on self-supervised learning from multimodal data to address a range of downstream clinical tasks. This review aims to critically discuss the potential of quantum computing (QC) to augment GMAI for more efficient data processing, medical imaging, drug discovery, and genomic analysis, owing to the inherent strengths of quantum superposition and entanglement that surpass the capabilities of classical AI/DL systems. Structural and technical trade-offs of this paradigm change are also discussed. We also give recommendations for safe bedside translation by facilitating a common assessment through clinician in the loop design, the CLAIM checklist, and the framework FUTURE-AI. Finally, this analysis outlines oncology and quantum convergence into quantum oncology (QO). This enables scalable, sustainable, and precision oncology while respecting ethics and privacy.
This research project presents a PRISMA-guided systematic literature review exploring the application of quantum machine learning (QML) in oncology, a rapidly growing field with fragmented evidence. The study synthesizes peer-reviewed studies from six databases (ACM, IEEE, MDPI, Scopus, Wiley, and PubMed) published between 2020 and 2026, screening 212 records and selecting 49 studies for analysis. The review examines clinical tasks, cancer domains, QML architectures, challenges, and future directions, revealing that current research mainly focuses on classification and detection, particularly in breast cancer and brain tumors, using hybrid quantum-classical models. Despite promising results, progress is limited by hardware constraints, simulator dependence, and insufficient clinical validation. The findings provide a clear overview of current QML trends and highlight future priorities, including real quantum hardware testing, diverse clinical datasets, standardized benchmarking, and stronger collaboration between computing and oncology communities.